Skip to content

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00540566
Enrollment
113
Registered
2007-10-08
Start date
1999-06-30
Completion date
2008-07-31
Last updated
2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Nevi, Basal Cell Carcinoma, Burns, Congenital Nevi, Dermatofibroma, Hemangioma, Kaposi's Sarcoma, Malignant Melanoma, Merkel Cell Carcinoma, Paget's Disease, Port Wine Stain, Scleroderma, Seborrheic Keratosis, Squamous Cell Carcinoma, Tattoos

Brief summary

This study is to compare the ability of optical biopsy. Research can use light enters the skin, collected, analyzed by the computer, and a picture created for the pathologist to conventional histologic examination compare with the pathologist looking at the piece of tissue through a microscope makes the diagnosis.

Detailed description

The Optical measurements provide quantitative optical property values that reflect changes in tissue perfusion, oxygen consumption, and cell/matrix development. Each measurement requires less than 5 minutes to execute. The measurements will be taken before and after skin treatment.This non-invasive, non-contact technique has great potential as a means to diagnose different skin problems without the need to obtain a piece of tissue from the skin.

Interventions

DEVICEOptical Biopsy imaging

Optical Biopsy imaging

Sponsors

Beckman Laser Institute University of California Irvine
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female age \> 18 years

Exclusion criteria

* current participation in any other investigational drug evaluation * inability to understand and carry out instructions

Design outcomes

Primary

MeasureTime frame
normal skin12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026